Corporate venture capital (CVC) has long been an important source of capital for early-stage biotechs and shows no signs of diminishing, with more and more biopharma companies stepping up their investment activity.
{iframe}http://www.fiercebiotech.com/biotech/pfizer-celgene-and-roche-are-climbing-pharma-vc-league-table{/iframe}